Sorafenib is an oral multikinase inhibitor approved by the US Food and Drug Administration
for treatment of the patients with surgically unresectable hepatocellular carcinoma (HCC) …

Background/Aim: We evaluated clinical factors related to improved prognosis of
unresectable hepatocellular carcinoma patients (u-HCC), who were treated with tyrosine …

Hepatocarcinogenesis is a multistep process, heralded by abnormalities in cell
differentiation and proliferation and sustained by an aberrant neoangiogenesis …

Background The present study aimed to investigate the impact of pre-sarcopenia on the
prognosis of patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib …

Background/Aim: Lenvatinib (LEN) has been developed for the treatment of unresectable
hepatocellular carcinoma (u-HCC). We aimed to elucidate the relative change in hepatic …

Abstract Background and Aim Albumin–bilirubin (ALBI) grade was developed as a new
method to assess hepatic function. Sorafenib has been confirmed to be effective in …

Simple Summary The combination of atezolizumab plus bevacizumab (Atz/Bev) is now
widely used in clinical practice as a first-line treatment for patients with advanced …

Background Sorafenib was approved for treatment of unresectable hepatocellular
carcinoma (HCC) in Japan in 2009. A prospective postmarketing all-patient surveillance …

Aim Cabozantinib (CAB), a multiple kinase inhibitor, has been approved for use in patients
with previously treated unresectable hepatocellular carcinoma (uHCC). However, real‐world …

Objective: To determine the relationship between treatment outcomes and hand-foot
syndrome (HFS), and the relationship between survival rate and post-progression treatment …